Physician

Curt F. Fenkl, D.O.

According to 2025 Medicare claims, Curt Fenkl, D.O. (NPI: 1447236476) practices dermatology in the Binghamton, NY market, with the plurality of this provider's patient population coming from Broome, NY. This provider's primary affiliated billing organization is SCHWEIGER DERMATOLOGY PLLC (NPI: 1831438662; TIN: 272373546) and primary practice location at 13850-3500. Fenkl is affiliated with the Physician Leaders Direct Contracting Entity, LLC (ACO ID: D0171) and Vytalize Health 9 ACO LLC (ACO ID: D0313), participating under the REACH model.

Fenkl's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 727 traditional Medicare patients, billed 3,431 HCPCS/CPT codes, and received $207,510 in Medicare payments. The top billing code was 17110 (Destruction of skin growth, 1-14 growths). Part D data shows 1,194 prescription claims across 465 beneficiaries totaling $929,239 in drug costs, led by Tremfya (Guselkumab). Open Payments data shows 169 records totaling $2,968. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $214,148 to $929,239. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	645	3,002	$195,529
2016	656	3,244	$197,113
2017	633	3,637	$220,742
2018	648	3,237	$188,001
2019	745	3,420	$185,863
2020	644	3,163	$189,121
2021	782	3,742	$221,056
2022	781	4,022	$249,093
2023	739	3,822	$207,835
2024	727	3,431	$207,510

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	399	802	$214,148
2016	400	938	$259,945
2017	382	877	$330,427
2018	373	972	$353,333
2019	428	1,055	$649,455
2020	440	1,020	$463,341
2021	429	1,017	$487,804
2022	395	1,003	$906,603
2023	413	1,058	$842,601
2024	465	1,194	$929,239

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
17110	Destruction of skin growth, 1-14 growths	187	216	$64
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	430	560	$59
99212	Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more	151	181	$35
17000	Destruction of precancer skin growth, 1 growth	226	315	$33
17003	Destruction of precancer skin growth, 2-14 growths	172	1,081	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tremfya	Guselkumab	13	728	$175,863
Humira(Cf) Pen	Adalimumab	18	504	$121,364
Dupixent Pen	Dupilumab	24	658	$88,788
Otezla	Apremilast	14	418	$67,243
Clobetasol Propionate	Clobetasol Propionate	108	2,886	$3,864

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	169	$2,968	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Curt F. Fenkl, D.O.?

Tedicare shows public-source Medicare data for Curt F. Fenkl, D.O. (NPI 1447236476), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Curt F. Fenkl, D.O. have ACO affiliation data?

Curt F. Fenkl, D.O. is shown with ACO affiliation data for Physician Leaders Direct Contracting Entity, LLC (REACH, ACO ID D0171) and Vytalize Health 9 ACO LLC (REACH, ACO ID D0313).

What billing organization is linked to Curt F. Fenkl, D.O.?

Curt F. Fenkl, D.O. is linked to SCHWEIGER DERMATOLOGY PLLC (billing NPI 1831438662) in the available physician profile data.

Does Curt F. Fenkl, D.O. have Open Payments data?

Curt F. Fenkl, D.O. has 169 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.